Innocan Pharma Hires Pain Expert for FDA Meeting Prep

HERZLIYA, Israel and CALGARY, Alberta, July 2, 2024 -- Innocan Pharma Corporation, a prominent player in the pharmaceutical and biotechnology sectors, has announced the engagement of Dr. William K. Schmidt, Past-President of the Eastern Pain Association. Dr. Schmidt will support Innocan's LPT-CBD submission process to the FDA for chronic pain treatment.

Iris Bincovich, CEO of Innocan, expressed her enthusiasm about Dr. Schmidt joining the team, highlighting his extensive knowledge in pain-related clinical development and regulatory affairs. His experience is expected to significantly bolster Innocan's efforts towards FDA approval for their LPT-CBD platform.

Dr. Schmidt boasts over 25 years of experience in the pharmaceutical industry, specializing in analgesic and narcotic antagonist drug development. His career includes pivotal roles in several pharmaceutical companies such as CrystalGenomics, Limerick BioPharma, Renovis, Inc., Adolor Corporation, and DuPont Merck. Notably, at Adolor Corporation, Dr. Schmidt was instrumental in the development and FDA approval of Entereg® (alvimopan), an opioid antagonist. At CrystalGenomics, he led the team responsible for the approval of Acelex® (polmacoxib) in South Korea. During his tenure at DuPont/DuPont Merck, he contributed to the development of nalbuphine (Nubain®), naltrexone (Trexan®, ReVia®), and the oxycodone-ibuprofen formulation used in Combunox™. Currently, Dr. Schmidt leads NorthStar Consulting, advising pharmaceutical and biotech firms worldwide on pain medicine development. He holds a BA from the University of California Berkeley and a PhD from the University of California San Francisco.

Innocan Pharma is a tech-driven pharmaceutical company that operates through two primary segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals division, Innocan is dedicated to developing innovative drug delivery platforms that integrate cannabinoid science to address various health conditions and enhance patients' quality of life. This division focuses on two primary drug delivery technologies. The first is the LPT CBD-loaded liposome platform, which facilitates precise dosing and the prolonged and controlled release of CBD into the bloodstream. This technology is currently in the preclinical trial phase for indications including epilepsy and pain management. 

The Consumer Wellness segment of Innocan is dedicated to developing and marketing a wide array of advanced self-care products aimed at promoting a healthier lifestyle. Under this segment, Innocan has also established a joint venture named BI Sky Global Ltd., which concentrates on developing advanced targeted online sales strategies.

Innocan Pharma continues to advance its innovative solutions in the pharmaceutical and biotechnology industries, with a strong commitment to improving health outcomes and patient quality of life through cutting-edge research and development.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!